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Introduction
Heart failure (HF) is a clinical syndrome with a pro-
gressive course that is caused by changes in the structure 
or function of the myocardium, leading to the impairment 
of systolic and/or diastolic myocardial function1,2. These 
changes reduce the heart’s ability to pump blood, resulting 
in a lack of adequate blood supply to the body. It is most 
commonly caused by diseases that affect the myocardium, 
but disorders that affect other parts of the cardiac system, 
including the pericardium, endocardium, heart valves and 
blood vessels can also lead to heart failure syndrome1. 
Most commonly, it is caused by coronary heart disease 
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A B S T R A C T
Heart failure with reduced ejection fraction (HFrEF) is a progressive clinical syndrome defined by changes in the 
myocardial structure, which lead to predominant systolic myocardial function impairment, with a left ventricle ejection 
of fraction ≤40%. The rehospitalization burden in HFrEF patients (pts) remains very high, with poor quality of life, in-
creased mortality and large healthcare expenditures. In this research project, we investigated the risk factors for first and 
repeated hospitalization in pts with HFrEF. This retrospective study included 50 adult pts with a diagnosis of HFrEF 
and who were within the age range of 55 to 89 years old and of both sexes. Demographic and clinical data (HFrEF etiology, 
renal function parameters, complete blood count, markers of inflammation, electrocardiogram, troponin I, NTproBNP, 
echocardiographic parameters and comorbidities data) were collected from the pts’ medical histories. Statistical analysis 
was performed via Fischer’s exact test, the Shapiro-Wilk test and the Spearman correlation coefficient. This study in-
cluded 70% male and 30% female HFrEF pts. Males were younger in both group of pts and had a higher incidence of 
rehospitalization. The most important HFrEF etiologic risk factors are arterial hypertension (82%), coronary heart disease 
(54%), atrial fibrillation (52%) and diabetes mellitus (40%). The most important noncardiac comorbidity related with the 
first HFrEF hospitalization is pneumonia (P=0.03), while progression of left ventricle systolic and diastolic dysfunction 
is related to rehospitalization risk (left ventricle end systolic diameter, P=0.003; diastolic dysfunction degree, P=0.04). 
The troponin level was associated with an increased risk of rehospitalization, but this was not statistically significant at 
this sample size (troponin I, p=0.10). Following the first and repeated hospitalizations of HFrEF pts, comorbidities, ageing 
and gender difference are crucial to HFrEF development, while echocardiographic parameters and biomarkers critically 
affect HFrEF rehospitalization risk.
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heart failure, patient readmission
(CHD), arterial hypertension (HTA), diabetes mellitus 
(DM) and atrial fibrillation (AF)2,3. Based on left ven-
tricular ejection fraction (LVEF), HF can be divided into 
heart failure with reduced ejection fraction (HFrEF < 40 %), 
mid-range EF (mrEF 40 – 49 %) and preserved EF 
 (HFpEF ≥ 50 %)1.
The epidemiology of HF is on the rise, and HF is now 
one of the most common causes of hospitalizations in de-
veloped western countries, at nearly one million hospital-
izations per year4. The overall prevalence is 1–2 % and 
increases in proportion with the patient’s age. Among 
those younger than 50 years old, it occurs in less than 1% 
of all cases, while it occurs in more than 10% of cases in 
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people more than 70 years old5. Heart failure can present 
as acute or chronic and can affect the left, right or both 
sides of the heart. Acute HF presents suddenly and is most 
commonly caused by massive myocardial infarction or 
papillary muscle rupture. On the other hand, chronic HF 
is longer in duration and usually caused by CHD, HA, 
cardiomyopathies and heart valve diseases6. HF is char-
acterized by classic symptoms that are most often accom-
panied by signs. Symptoms include dyspnea, orthopnea, 
paroxysmal nocturnal dyspnea, nocturia, fatigue and 
weakness. Some of the most common signs that accom-
pany these symptoms include distended jugular veins of 
the neck, auscultatory third heart tone (gallop rhythm), 
bilateral auscultatory wheezing, hepatomegaly and pe-
ripheral edema of the legs7. However, the symptoms are 
nonspecific and difficult to distinguish from those of oth-
er diseases, especially in the elderly, obese, and pts with 
chronic lung disease8. Heart failure can be functionally 
classified using the NYHA classification system, based on 
whether symptoms occur during exertion or even while at 
rest9. Heart failure should already be suspected based on 
the clinical presentation and confirmed with the HF bio-
marker N-terminal pro b-type natriuretic peptide (NT-
proBNP). In addition to making a diagnosis, NTproBNP 
is used in the gradation of the disease and as a response 
to therapy. Due to the volume and pressure load that oc-
curs in pts with HF, NTproBNP is released into the blood-
stream1. Patients whose plasma values are within the 
reference values usually do not have HF, while in pts with 
elevated values, further diagnostic processing is required1. 
Echocardiography is used as the gold standard in diagno-
sis because it provides information on the structure and 
function of the myocardium, valvular diseases, heart 
chamber volumes and hemodynamics10.
HF is most commonly associated with a number of 
other serious diseases that affect the stability of the dis-
ease itself, increase the need for rehospitalization, worsen 
clinical status, and lower the outcome of the predictors. 
The presence of comorbidities can affect the choice of med-
ications, while comorbidity medications can result in a 
significant worsening of HF11. Age, sex, etiology, LVEF, 
NYHA classification, NTproBNP, and the presence of nu-
merous comorbidities negatively affect disease prognosis 
and increase the risk of rehospitalization, especially with-
in the first month1. The most common cardiac and noncar-
diac comorbidities include AF, HA, CHD, DM, asthma, 
chronic obstructive pulmonary disease (COPD), periph-
eral arterial disease, valvular defects, anemia, hyperlip-
idemia and malignancies12. The need for rehospitalization 
is a negative prognostic factor, and it affects the further 
deterioration of LVEF and increases the risk of morbidity 
and mortality. Over the past thirty years, advances in 
treatment have reduced the need for hospitalization, al-
though the outcomes often remain unsatisfactory1.
The main purpose of this study is to obtain data about 
HFrEF pts, their comorbidities and other medical param-
eters which could cause HF worsening and the need for 
first and repeated hospitalization. 
Materials and Methods
This research presents a cross-sectional retrospective 
study. The study included 50 adult patients (pts) of both 
sexes, with age ranging from 55 to 89 years and with a 
diagnosis of heart failure with reduced ejection fraction 
(HFrEF), treated during 2019 (from January to June), at 
the Department for Heart and Vessel Disease, Osijek Uni-
versity Hospital. The research was approved by the Ethics 
Committee of the Medical Faculty Osijek and the Ethics 
Committee of the Osijek University Hospital. 
Demographic and clinical data were collected from the 
pts ’medical histories in the available medical records 
(electronic database). The inclusion criteria for the study 
was diagnosis of HFrEF according to hospital discharge 
letter, diagnosis made according to recent European Car-
diology Guidelines for Heart Failure, 2016. The exclusion 
criteria for the study were diagnosis of heart failure with 
preserved ejection fraction, unclear diagnosis and incom-
plete medical documentation. 
The parameters used in the research include age, gen-
der, etiology of HFrEF, biochemical parameters: electro-
lytes – sodium and potassium, renal function parameters 
– urea and creatinine, complete red blood count – eryth-
rocytes, hemoglobin, hematocrit and MCV, C-reactive pro-
tein, troponin I, NTproBNP; electrocardiographic data 
(ECG) – sinus rhythm or atrial fibrillation with the fre-
quency data; echocardiographic parameters provided in 
routine clinical practice according to European Associa-
tion of Cardiovascular Imaging recommendation: left 
 ventricle ejection fraction – LVEF, left ventricle and left 
atrium diameters, stage of the diastolic dysfunction; 
 comorbidities data. 
The pts with HFrEF were divided into two groups ac-
cording to the number of hospitalizations because of 
HFrEF worsening, first hospitalization and rehospitaliza-
tion. The general, biochemical, hemodynamic and echo-
cardiographic parameters were analyzed in both groups 
and HFrEF pts.
Categorical data were presented in terms of absolute 
and relative frequencies. Differences in categorical vari-
ables were tested via Fisher’s exact test. The normality of 
the distribution of the numerical variables was tested via 
the Shapiro-Wilk test. Numerical data are described via 
the median and the limits of the interquartile range. The 
differences in the numerical variables between the two 
independent groups were tested via the Mann-Whitney 
U-test. The correlation between the variables was as-
sessed via the Spearman correlation coefficient (Rho). All 
P-values are two-sided. The significance level was set to 
Alpha = 0.05. MedCalc Statistical Software Version 19.1.7 
(MedCalc Software Ltd, Ostend, Belgium; https://www.
medcalc.org; 2020) was used for statistical analysis.
Results
The study included 50 adult pts of both sexes, of whom 
70% were male and 30% were female. These pts were di-
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higher in those who were hospitalized for the first time, 
P=0.03 (Table 1).
The median systolic blood pressure at the first hospi-
talization was 128 mmHg, while at repeated hospitaliza-
tion, this value was 120 mmHg, with P=0.10. There were 
no changes in diastolic blood pressure regardless of the 
number of hospitalizations, and the median value was 70 
mmHg. Patients hospitalized for the first time had sig-
nificantly higher heart rates than rehospitalized pts (P = 
0.04), with a median of 94 (interquartile range of 83 to 
114). Markers of cardiac ischemia, specifically troponin I, 
showed no significant correlation at this sample size, but 
the P-value was 0.10. A marker of heart failure, NTproB-
NP, showed increased values at rehospitalization in terms 
of total numbers, but this was without statistical signifi-
cance (Table 2, Figure 1, Figure 2). 
Echocardiographic data showed significant results in 
terms of their use as prognostic parameters in rehospital-
ized pts. Endsystolic LV diameter was significantly dilated 
in pts who underwent repeated hospitalization (P=0.003), 
and the degree of diastolic dysfunction was significantly 
higher in rehospitalized pts as compared to pts hospital-
ized for the first time (P=0.04). At this sample size, end 
diastolic LV diameter and LA diameter showed no signifi-
cant correlation, but there were p-values 0.09 for end dia-
stolic LV diameter and 0.08 for LA diameter (Table 3).
vided into two groups based on the number of previous 
hospitalizations. The first group consisted of the 42% of 
patients for whom this was the first hospitalization, while 
the second group consisted of the 58% who were hospital-
ized more than once. The median age for all pts was 76 
years old (interquartile range 66 to 82 years). At the first 
hospitalization, the median age was 79, and at repeated 
hospitalization, the median age was 70 years old. Male pts 
were younger in both groups (first hospitalization at 78 
years old, repeated hospitalization at 68,5 years old), and 
females were older in both groups (first hospitalization at 
81.5 years old, repeated hospitalization at 80 years old).
The most common HFrEF etiologies included HTA 
(82% pts), CHD (54%) and DM (40% pts), regardless of 
whether this was the patients’ first hospitalization or a 
rehospitalization. Regarding the causes of HFrEF, 24% of 
pts had severe aortic valve stenosis, and 14% had severe 
mitral regurgitation. Among included pts, CHD was treat-
ed with percutaneous coronary intervention (PCI), coro-
nary artery bypass grafting (CABG) and optimal medical 
therapy. Serious arrythmias were treated with implant-
able cardiac devices, such as pacemakers, cardioverter 
defibrillators and cardiac resynchronization therapy defi-
brillators (Table 1). The most common comorbidity was 
COPD, which presented in 20% pts, regardless of whether 
they were hospitalized for the first time or rehospitalized. 
The percentage of pts with pneumonia was significantly 
TABLE 1
CHARACTERISTICS OF HOSPITALIZED PATIENTS WITH HFrEF
1st hospitalization
Number of subjects (%)
1st hospitalization Rehospitalization Total P*
Gender
Male 13 (62) 22 (76) 35 (70) 0 .36
Female 8 (38) 7 (24) 15 (30) 0 .36
Diabetes mellitus 8 (38) 12 (41) 20 (40) >0 .99
Arterial hypertension 19 (91) 21 (75) 40 (82) 0 .27
Coronary heart disease 
(CHD) 13 (62) 14 (48) 27 (54) 0 .40




intervention (PCI) 2/13 6/14 8/27 0 .31
Medical therapy 7/13 4/14 11/27 0 .31
Coronary artery bypass  
grafting (CABG) 4/13 4/14 8/27 0 .31
Aortic valve stenosis 
(gravis) 3 (14) 9 (31) 12 (24) 0 .20
Mitral regurgitation 
(gravis) 4 (19) 3 (10) 7 (14) 0 .43




difibrillator (ICD) 2/3  4/9 6/12 > 0 .99
Pacemaker 1/3  4/9 5/12 > 0 .99
Cardiac resyncronisation 
therapy defibrillator (CRT-D) 0/3  1/9 1/12 > 0 .99
*Fisher’s exact test;  HFrEF – heart failure with reduced ejection fraction
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Atrial fibrilliation was present in 52% of pts, and sinus 
rhythm was present in 48% of pts, regardless of whether 
it was their first hospitalization or a rehospitalization. 
Rehospitalized pts with AF had significantly lower values 
for LVEF than pts hospitalized for the first time (P=0.03) 
(Figure 3).
This study did not find significant differences in bio-
chemical blood analysis (complete blood count, electrolytes, 
renal function and inflammatory markers) (Table 2).
Discussion
HF is the most prominent cause of hospitalization glob-
ally2,12. The rehospitalization burden in HFrEF pts re-
mains very high, with poor quality of life, increased mor-
tality and large healthcare expenditures13. In the HF 
population, noncardiac comorbidities often coexist and 
have an adverse effect on outcome. The prevalence and 
prognostic impact of noncardiac comorbidities in pts with 
TABLE 2
COMORBIDITIES OF HOSPITALIZED PATIENTS WITH HFrEF
Number of subjects (%)
1st hospitalization Rehospitalization Total P*
Non-Hodgkin lymphoma 0 1 (3) 1 (2) > 0 .99
Breast cancer 2 (9) 0 2 (4) 0 .17
Prostate cancer 0 2 (7) 2 (4) 0 .50
Chronic obstructive pulmorary disease 3 (14) 7 (24) 10 (20) 0 .49
Pulmonary silicosis 0 1 (3) 1 (2) >0 .99
Gastritis 0 1 (3) 1 (2) >0 .99
Cerebrovascular insult 2 (9) 4 (14) 6 (12) >0 .99
Anemia 1 (5) 2 (7) 3 (6) >0 .99
Periferal arterial disease 0 2 (7) 2 (4) 0 .50
Urinary bladder cancer 0 1 (3) 1 (2) >0 .99
Pneumonia 4 (19) 0 4 (8) 0 .03†
Rheumatoid arthritis 1 (5) 0 1 (2) 0 .42
Internal carotid arterry stenosis 0 1 (3) 1 (2) >0 .99
Hyperthyreosis 0 1 (3) 1 (2) >0 .99
Colon polypes 0 1 (3) 1 (2) >0 .99
Abdominal aortic aneurysm 1 (5) 0 1 (2) 0 .42
Nephrectomy 0 1 (3) 1 (2) >0 .99
Thromboembolism 0 1 (3) 1 (2) >0 .99
Pulmonary thromboembolism 0 2 (7) 2 (4) 0 .50
Deep vein thrombosis 0 1 (3) 1 (2) >0 .99
Collagenosis 0 1 (3) 1 (2) >0 .99
Basal-cell carcinomas 0 1 (3) 1 (2) >0 .99
*Fisher’s exact test;  † results with statistical significance;  HFrEF – heart failure with reduced ejection fraction
Fig. 1. Troponin I level in in first and repeated hospitalization 
in HFrEF patients. 
HFrEF – heart failure with reduced ejection fraction.
Fig. 2. NTproBNP level in first and repeated hospitalization in 
HFrEF patients. NTproBNP - N-terminal pro b-type natriuretic 
peptide; HFrEF – heart failure with reduced ejection fraction.
143
K. Selthofer-Relatić et al.: Indicators for HFrEF Patients’ Rehospitalization, Coll. Antropol. 44 (2020) 3: 139–145
HFrEF remain inadequately studied14. Across all comor-
bidities examined in trials with HF, data were reported 
for a mean of 35% of trials (51% in HFrEF trials and 27% 
in HFpEF trials). Among cardiac comorbidities, the most 
important were HTA (63%), CHD (44%), hyperlipidaemia 
(48%), DM (33%) and AF (25%), while the most important 
noncardiac comorbidity was chronic kidney disease (CKD) 
(25%). Many HF trials do not report baseline comorbidi-
Fig. 3. The difference in NTproBNP level in first and repeated hospitalization, in HFrEF patients with sinus rhythm and atrial 
fibrillation. HFrEF – heart failure with reduced ejection fraction
TABLE 3





erythrocytes 4.32 (4.1–4.8) 4.46 (4.1–4.96) 0.86
hemoglobin 138 (117.5–147.5) 134 (119.5–146) 0.52
Hematocrit 0.41 (0.4–0.4) 0.4 (0.36–0.43) 0.55
MCV 90.1 (83.6–95.8) 87.2 (84.1–89.6) 0.20
Electrolytes
sodium 139 (137.5–140.5) 139 (134–141) 0.40
potassium 4.3 (3.8–4.6) 4.2 (4–4.6) 0.59
Renal function
urea 7.9 (5.8–12.1) 8.4 (7.3–13.4) 0.37
creatinine 93 (77–139) 98 (82.5–135) 0.81
C-reactive protein 12.2 (3.9–38.2) 7.7 (3.4–17.4) 0.21
Blood pressure Systolic 128 (110–158) 120 (106.5 – 130) 0.09‡
Diastolic 70 (67–100) 70 (63 – 80) 0.38
ECG Heart rate 100 (92–121) 90 (71 – 109) 0.04†
Troponin I 0.051 (0.024–0.186) 0.191 (0.041 – 0.554) 0.10‡




LVEF 30 (25–35) 27 (21–32) 0.18
EDD LV 56 (49.5–60) 59.5 (54.3–63.8) 0.09‡
ESD LV 46 (40–50) 51 (49–55) 0.003†
DD degree 1 (1–2) 2 (2–2) 0.04†
TAPSE 16.5 (13.3–19.8) 14 (12–17) 0.16
LA 48.5 (44.5–50.3) 51 (46.3–56.8) 0.08‡
*Mann Whitney U test; † results with statistical significance;  ‡ results without statistical significance, but with p ≤ 0.10
HFrEF – heart failure with reduced ejection fraction; 2D TTE – two dimensional echocardiographic parameters; ECG – electrocardiogram; 
NTproBNP – N-terminal pro b-type natriuretic peptide; LVEF – left ventricle ejection fraction; EDD LV – left ventricle enddiastolic diameter; 
ESD LV – left ventricle endsystolic diameter; DD – diastolic dysfunction; TAPSE – tricuspid annular plane systolic excursion; LA – paraster-
nal left atrial diameter;
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ties. A more systematic approach must be adopted for fu-
ture clinical trials to ensure adequate cardiac and noncar-
diac comorbidity reporting and improve the recruitment 
of multimorbid HF pts14.
The data in our study are in line with those of previous 
studies. HF rarely occurs as an isolated case. The most 
common cardiac and noncardiac comorbidities include 
HTA, CHD, DM, AF, CKD and COPD. Although no sta-
tistical significance has been proven in relation to wheth-
er this is the first hospitalization or rehospitalization, the 
incidence rates for HTA, CHD, DM and AF are even 
higher in our study than those previously reported3. In 
our study, 82% of all pts were diagnosed with HTA. Al-
though HTA is one of the most common comorbidities as-
sociated with HF, according to the latest European Car-
diac Guidelines, it is usually well regulated in treated pts1. 
CHD is the next most common comorbidity, leading to a 
worse prognosis and poorer outcomes than in pts without 
CHD. Our results are in line with a study conducted on 
1,200 pts diagnosed with HFrEF, which showed that the 
mortality rate was high, regardless of whether this condi-
tion was treated with conservative drugs or combined in-
vasive therapy (68% versus 58%)15. DM was the third 
most common comorbidity in the study (40%). Unregu-
lated DM increases the number of hospitalizations and 
negatively affects HF, which is in line with a study con-
ducted on 2,500 pts, in which an increase in HbA1c above 
8.6% caused a 36.2% increase in hospitalizations16. Atrial 
fibrillation was present in 52% of HFrEF pts at the first 
hospitalization, with significantly better LVEF as com-
pared to rehospitalized pts with AF and a lower degree of 
LVEF. The results obtained indicate that prolonged AF, 
along with other comorbidities, leads to worsening LVEF 
and thus worsening outcomes for HF. Rehospitalized 
HFrEF pts had significantly lower heart rates as com-
pared to those hospitalized for the first time. The cause of 
this may be the sinus atrial node being affected by myo-
cardial disease, or it could be a result of HFrEF treatment. 
The goal of treatment for these pts is to return to a proper 
heart rate17. As a marker of HF, NTproBNP is used as an 
initial tool for performing diagnosis, disease graduation 
and follow up. The results of the study did not prove a 
statistically significant difference in the number of hospi-
talizations between the groups, although rehospitalized 
pts had higher NTproBNP values as compared to first-
time hospitalizations, indicating the greater impairment 
of systolic and diastolic function in rehospitalized pts18. 
This was also indicated by the results obtained via further 
echocardiographic processing. Rehospitalized pts had sig-
nificantly higher LV diameter values during systole and 
a significantly higher degree of diastolic dysfunction than 
those hospitalized for the first time19,20. HF is a disease 
that primarily affects the elderly population. One such 
cohort study was conducted in Rotterdam on around 8,000 
pts who were hospitalized with a diagnosis of HF.
 This study demonstrated an increase in prevalence in 
proportion to the increase in the age of pts, from 0.9% 
between the ages of 55 and 64 to almost 10% between the 
ages of 75 and 84. The average age of the pts in the study 
was 74.5 years, and HF affected men slightly more fre-
quently than women21. COPD is present in 20% of pts and 
is more common in pts diagnosed with HF than in healthy 
people. This is line with the Cardiovascular Health study 
that in a sample of almost 5,000 subjects, obtained similar 
results22. The symptoms and signs of COPD are often in-
tertwined with the clinical picture of HF, making it dif-
ficult to perform a diagnosis. Pneumonia occurs signifi-
cantly more frequently in pts hospitalized for the first time 
as opposed to rehospitalized pts (19%). These pts also had 
slightly higher CRP values than those hospitalized mul-
tiple times, although not significantly so. However, pneu-
monia may not be the only cause of this elevated marker 
of inflammation23. Other examined biochemical parame-
ters, such as renal function and complete blood count, did 
not show any significance in our study, which may be due 
to the duration and the course of the comorbidities and 
disease. 
Conclusion
In this retrospective HFrEF analysis, we have seen 
that cardiac comorbidities in our population have even 
higher incidence than previously reported, which is di-
rectly related with the risk of the first hospitalization, 
together with gender and age. Noncardiac comorbidities 
have an important role in HFrEF manifestation and time 
to repeated hospitalization, which is directly related with 
the progressive decay of HF stage. In this group of pts, 
pnemonia was important for the first hospitalization, and 
COPD is the most common noncardiac comorbidity re-
gardless of the number of hospitalizations. Echocardio-
graphic parameters related to morphologic, functional and 
hemodinamic changes caused by cardiac and noncardac 
diseases are crucial to HFrEF rehospitalization risk. Our 
study has several limitations: the number of included pts, 
the data obtained from the medical files, limited informa-
tion on the degrees and duration of the comorbidities.
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PROGNOSTIČKI POKAZATELJI PRVE I PONOVLJENE HOSPITALIZACIJE KOD PACIJENATA SA 
SRČANIM ZATAJIVANJEM S REDUCIRANOM EJEKCIJSKOM FRAKCIJOM LIJEVE KLIJETKE
S A Ž E T A K
Srčano popuštanje s reduciranom ejekcijskom frakcijom (HFrEF) progresivni je klinički sindrom definiran struk-
turnim promjenama miokarda koji dovodi prvenstveno do oštećenja sistoličke funkcije s redukcijom ejekcijske frakcije 
lijeve klijetke ≤40 %. Učestalost ponovne hospitalizacije pacijenata s HfrEF-om vrlo je visoka, smanjuje kvalitetu života, 
povećava stopu smrtnosti i veliko je financijsko opterećenje zdravstvenome sustavu. U istraživanju su proučavani rizični 
čimbenici za prvu i ponovnu hospitalizaciju kod pacijenata s HfrEF-om. U ovu retrospektivnu studiju uključeno je 50 
odraslih pacijenata s dijagnozom HfrEF-a, životne dobi između 55 i 89 godina, oba spola. Demografski i klinički podaci 
(etiologija HfrEF-a, parametri bubrežne funkcije, kompletna krvna slika, biljezi upale, elektrokardiogram, troponin I, 
NTproBNP, ehokardiografski parametri, komorbiditeti) prikupljeni su iz medicinske dokumentacije pacijenata. 
Statistička analiza učinjena je Fischerovim egzaktnim testom, Shapiro-Wilk testom i Spearmanovim koeficijentom 
korelacije. U studiju je uključeno 70% muškaraca i 30% žena s HfrEF-om, muškarci su u obje praćene skupine bili mlađe 
životne dobi te su imali veću incidenciju rehospitalizacije. Najznačajniji etiološki čimbenici rizika za HFrEF su arteri-
jska hipertenzija (82%), koronarna bolest (54%), atrijska fibrilacija (52%), šećerna bolest (40%). Od nekardioloških ko-
morbiditeta vezanih uz prvu hospitalizaciju pacijenata s HfrEF-om najznačajnija je pneumonija (P = 0,03), dok je 
pogoršanje sistoličke i dijastoličke funkcije lijeve klijetke vezano uz ponovnu hospitalizaciju (end-sistolički promjer lijeve 
klijetke, P = 0,003; stupanj dijastoličke disfunkcije, P = 0,04). Biomarker troponin I pokazao je tendenciju porasta u 
rehospitalizaciji, ali bez statističke značajnosti na ovoj veličini uzorka (troponin I, p = 0,10). Komorbiditeti, starenje i 
spol ključni su za razvoj HFrEF-a, dok su ehokardiografski parametri i biomarkeri ključni za rehospitalizaciju.
